Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Moderna, Inc.NASDAQ: MRNA

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin widens to 12.3%

Net margin was 12.3% in Q3 FY2026, up 32.0 pp from a year earlier. On a trailing-twelve-month basis it was -110.5%, up 29.8 pp year over year. Over 3 fiscal years it narrowed by 189.5 pp.

Context

  • Net margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 14 analysts of -126.2% for the fiscal year ending Dec 2026, up from -145.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
12.3%+551.6 pp QoQ
Last fiscal yearDec 2025
-145.2%-33.8 pp YoY
LTMSep 2026
-110.5%+29.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+32.0 pp-44.2 pp-76.2 pp
1 year-33.8 pp+19.0 pp+52.8 pp
3 years-189.5 pp+116.4 pp+305.9 pp
5 years+165.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-145.2%
Year-over-year change
-33.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MRNA compares with its peers on the latest reported figures

  • MRNA's LTM Sep 2026 net margin of -110.5% is the 6th highest of the 9 companies compared; the peer median is -76.2%.
  • Its year-over-year change of +29.8 pp is the 2nd highest of 9, against a peer median of -48.6 pp.
  • Over three fiscal years its change of -189.5 pp compares with a peer median of -63.8 pp.
MRNA Competitors Peer median
Net Margin for MRNA and competitors
Company Period LTM level YoY 3-year change
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
NVAXNovavax, Inc.LTM Mar 2026-14.7% -52.9 pp+80.3 pp
BNTXBioNTech SELTM Jun 2026-64.0% -52.0 pp-94.1 pp
VALNValneva SELTM Mar 2026-88.3% -45.1 pp-26.3 pp
MRNAModerna, Inc.LTM Sep 2026-110.5% +29.8 pp-189.5 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-173.5% -123.0 pp-102.4 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-676.0% +2093.1 pp-670.8 pp
INOInovio Pharmaceuticals, Inc.FY2025-130000.0% -80745.7 pp-127273.3 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding MRNA) -76.2%-48.6 pp-63.8 pp

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.74B18.88B6.85B3.2B1.94B
Cost of Revenue2.62B5.42B4.69B1.46B868M
Gross Profit15.12B13.46B2.16B1.74B1.08B
Gross Margin85.2%71.3%31.5%54.2%55.3%
Research & Development1.99B3.3B4.85B4.54B3.13B
Selling, General & Admin567M1.13B1.55B1.17B1.02B
Operating Expenses1.82B4.04B6.39B5.68B4.15B
Depreciation & Amortization232M348M621M189M215M
EBITDA13.54B9.95B(3.28B)(3.39B)(2.55B)
EBITDA Margin76.3%52.7%-47.9%-106.1%-131.3%
Operating Income13.3B9.42B(4.24B)(3.95B)(3.07B)
Operating Margin75.0%49.9%-61.9%-123.3%-158.1%
Interest Income18M200M421M425M314M
Interest Expense18M29M38M24M10M
Other Income / Expenses(11M)155M297M338M306M
Income Before Tax13.29B9.58B(3.94B)(3.61B)(2.77B)
Pre-Tax Margin74.9%50.7%-57.6%-112.8%-142.4%
Income Tax Expense1.08B1.21B772M(46M)54M
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Net Margin68.8%44.3%-68.8%-111.3%-145.2%
EPS (Basic)30.3121.26(12.34)(9.27)(7.26)
EPS (Diluted)28.2920.10(12.34)(9.27)(7.26)
Weighted Avg Shares403M394M382M384M389M
Weighted Avg Shares (Diluted)431M416M382M384M389M

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.